These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38836284)

  • 1. Sodium-Glucose Cotransporter 2 Inhibitor Improves Neurological Outcomes in Diabetic Patients With Acute Ischemic Stroke.
    Yang W; Kim JM; Chung M; Ha J; Kang DW; Lee EJ; Jeong HY; Jung KH; Sung H; Paeng JC; Lee SH
    J Stroke; 2024 May; 26(2):342-346. PubMed ID: 38836284
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
    Lee S; Zhou J; Leung KSK; Wai AKC; Jeevaratnam K; King E; Liu T; Wong WT; Chang C; Wong ICK; Cheung BMY; Tse G; Zhang Q
    Cardiovasc Drugs Ther; 2023 Jun; 37(3):561-569. PubMed ID: 35142921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperglycemia in acute ischemic stroke: physiopathological and therapeutic complexity.
    Ferrari F; Moretti A; Villa RF
    Neural Regen Res; 2022 Feb; 17(2):292-299. PubMed ID: 34269190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose sodium-glucose cotransporter 2 inhibitor ameliorates ischemic brain injury in mice through pericyte protection without glucose-lowering effects.
    Takashima M; Nakamura K; Kiyohara T; Wakisaka Y; Hidaka M; Takaki H; Yamanaka K; Shibahara T; Wakisaka M; Ago T; Kitazono T
    Commun Biol; 2022 Jul; 5(1):653. PubMed ID: 35780235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incident heart failure, arrhythmias and cardiovascular outcomes with sodium-glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database.
    Fawzy AM; Rivera-Caravaca JM; Underhill P; Fauchier L; Lip GYH
    Diabetes Obes Metab; 2023 Feb; 25(2):602-610. PubMed ID: 36054168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-Glucose Cotransporter-2 Inhibitor Prevents Stroke in Patients With Diabetes and Atrial Fibrillation.
    Chang SN; Chen JJ; Huang PS; Wu CK; Wang YC; Hwang JJ; Tsai CT
    J Am Heart Assoc; 2023 May; 12(10):e027764. PubMed ID: 37183872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Narrative review investigating the nephroprotective mechanisms of sodium glucose cotransporter type 2 inhibitors in diabetic and nondiabetic patients with chronic kidney disease.
    Speedtsberg ES; Tepel M
    Front Endocrinol (Lausanne); 2023; 14():1281107. PubMed ID: 38174341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of preoperative sodium-glucose cotransporter 2 inhibitors on the incidence of perioperative metabolic acidosis: A retrospective cohort study.
    Iwasaki Y; Sasabuchi Y; Horikita S; Furukawa T; Shiotsuka J; Lefor AK; Sanui M
    BMC Endocr Disord; 2022 Aug; 22(1):209. PubMed ID: 35987618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ratio of free triiodothyronine to free thyroxine is regulated differently in patients with type 2 diabetes mellitus treated and not treated with sodium glucose cotransporter 2 inhibitors.
    Okada S; Isoda A; Hoshi H; Okada J; Okada K; Yamada E; Saito T; Watanabe T; Kikkawa K; Ohshima K
    Diabetes Metab Syndr; 2023 Jan; 17(1):102704. PubMed ID: 36621107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canagliflozin, an Inhibitor of the Na
    Shim B; Stokum JA; Moyer M; Tsymbalyuk N; Tsymbalyuk O; Keledjian K; Ivanova S; Tosun C; Gerzanich V; Simard JM
    Cells; 2023 Sep; 12(18):. PubMed ID: 37759444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of sodium-glucose cotransporter 2 inhibitors during the perioperative period: A retrospective comparative study.
    Ge V; Subramaniam A; Banakh I; Wang WC; Tiruvoipati R
    J Perioper Pract; 2021 Oct; 31(10):391-398. PubMed ID: 32894998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
    Dong YH; Chang CH; Lin JW; Yang WS; Wu LC; Toh S
    Diabetes Obes Metab; 2022 Aug; 24(8):1623-1637. PubMed ID: 35491533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes in heart failure patients with and without atrial fibrillation receiving sodium-glucose cotransporter-2 inhibitor.
    Hu WS; Lin CL
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Sep; 396(9):1977-1986. PubMed ID: 36881169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-glucose Cotransporter 2 Inhibitors and Ischemic Stroke.
    Milonas D; Tziomalos K
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):134-138. PubMed ID: 29412119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between sodium-glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation.
    Fichadiya A; Quinn A; Au F; Campbell D; Lau D; Ronksley P; Beall R; Campbell DJT; Wilton SB; Chew DS
    Europace; 2024 Mar; 26(3):. PubMed ID: 38484180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong.
    Lui DTW; Tang EHM; Wu T; Au ICH; Lee CH; Woo YC; Tan KCB; Wong CKH
    Cardiovasc Diabetol; 2023 Feb; 22(1):40. PubMed ID: 36829226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection of ischemic myocardium in diabetics by inhibition of electroneutral Na+-K+-2Cl- cotransporter.
    Ramasamy R; Payne JA; Whang J; Bergmann SR; Schaefer S
    Am J Physiol Heart Circ Physiol; 2001 Aug; 281(2):H515-22. PubMed ID: 11454552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of admission random glucose, fasting glucose, and glycated hemoglobin in predicting the neurological outcome of acute ischemic stroke: a retrospective study.
    Sung JY; Chen CI; Hsieh YC; Chen YR; Wu HC; Chan L; Hu CJ; Hu HH; Chiou HY; Chi NF
    PeerJ; 2017; 5():e2948. PubMed ID: 28168113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Sodium/Glucose Cotransporter Inhibitors on Atrial Fibrillation and Stroke: A Meta-Analysis.
    Ong HT; Teo YH; Teo YN; Syn NL; Wee CF; Leong S; Yip ASY; See RM; Ting AZH; Chia AZ; Cheong AJY; Tan BY; Ho JS; Yeo LL; Leow AS; Yeo TC; Wong RC; Chai P; Kojodjojo P; Sia CH
    J Stroke Cerebrovasc Dis; 2022 Jan; 31(1):106159. PubMed ID: 34689051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study.
    Chen TH; Li YR; Chen SW; Lin YS; Sun CC; Chen DY; Mao CT; Wu M; Chang CH; Chu PH; Wu VC
    Cardiovasc Diabetol; 2020 Nov; 19(1):189. PubMed ID: 33167990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.